** Shares of generic drugmaker Viatris VTRS.O fall 11.3% to $9.97 premarket
** Co forecast 2025 revenue to be between $13.5 bln and $14 bln, below analysts' est of $14.27 bln - LSEG
** Co expects 2025 adj profit between $2.12/shr and $2.26/shr, compared with estimates of $2.59/shr - LSEG
** VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 mln and adjusted core earnings by roughly $385 mln.
** Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations
** Co also reports Q4 adj profit of 54 cents/shr, below analysts' est of 57 cents/shr - LSEG
** Co posts Q4 sales of $3.52 bln, below analysts' est of $3.61 bln - LSEG
** VTRS gained 8.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。